The Intelligence Diaries - Pharmaceutical Executive

ADVERTISEMENT

The Intelligence Diaries
Here's your study guide to what the industry once knew—and lost.


Pharmaceutical Executive


Marker #1: A crisis of reputation Last year, Harris Interactive's reputation poll of 21 industries placed pharmaceuticals among the most unpopular—again. Certainly, pharma's bad rep is nothing new, but things have gone from bad to worse. This crisis of reputation has forced pharmaceutical firms to report their trials, inform the public about changes in strategy, and disclose pricing of drugs.


How Vasella Interprets Data—and the Future
"We are close to the bottom of the barrel," commented Wayne Rosenkrans, a strategist for AstraZeneca. "We are just a notch above the tobacco industry. We went from just being greedy to being evil about a year ago."

It's not surprising then that, since 2000, pharmas worldwide have paid nearly $4 billion in settlements and fines.

Marker #2: The technology "revealer" It used to be that companies gained intelligence on how their drugs were faring in the marketplace through periodically updated reports from IMS Health. But new modes of delivery for medical data are creating a quiet revolution. Companies now gain this insight instantaneously by connecting with doctors at the point of prescribing and speeding intelligence directly to decision makers. To do this, the industry relies upon vendors that collect information from doctors with handheld devices, or from contract market researchers who survey physicians.


Did You Know?
"Many biotech products are carried and distributed by specialty pharmacies...[and] may require special handling," says Allen Kamer, director of business development for Leerink Swann & Company, a healthcare-focused investment bank. "In order to stay current with...demand, companies require real-time data and information about their products."

Marker #3: Government's heavy hand Over the past decade, the US government has forced open the doors to what used to be considered insider information. One of the best examples came in 1997 when FDA began requiring companies to register clinical trials and then posted the list on clinicaltrials.gov/.

The transparency juggernaut driven by government is gaining speed. Even now, the US government has begun to move aggressively into the field of outcomes research, also known as health economics (which leads us to the next marker.)

Marker #4: Health economics and stealth agencies It used to be that slightly differentiating a drug was enough to get it on the formulary. Now, robust outcomes analyses that demonstrate significant advantages are needed if a drug's potential market success is to be realized.


Who Receives the Message?
The Agency for Healthcare Research and Quality, part of the Department of Health and Human Services, is at the forefront of applying health economics to the healthcare system. Its agenda may determine profit margins for the industry for years to come. Yet, AHRQ is virtually unknown by industry analysts.

"AHRQ is going to have a great impact on our industry," says Rosenkrans. "What it is doing is centered on comparative effectiveness, which has input into formulary decisions in ways that people don't really appreciate. I can't tell you how many times when I speak in front of audiences and ask them what AHRQ is that not a single hand goes up!"


ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here